Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ANTIHISTAMINE WARNING STATEMENT ON USE IN ASTHMA PATIENTS SHOULD BE DELETED "AS SOON AS POSSIBLE," FDA’s PULMONARY-ALLERGY COMMITTEE CONCLUDES

Executive Summary

The warning statement in both OTC and Rx antihistamine labeling that contraindicates use in asthma patients should be removed, FDA's Pulmonary-Allergy Drugs Advisory Committee recommended at its June 12 meeting. Committee Chairman Leonard Bernstein, MD, University of Cincinnati Medical Center, asked the group: "Do we as a committee now wish to recommend that the statement about possible adverse effects of antihistamines in the treatment of asthma be rescinded as soon as possible?" All of the members, with one abstention, voted affirmatively in response to the question. There were no "opposing" votes. In a presentation on the use of antihistamines in asthma patients, FDA consultant William Pierson, MD, University of Washington, asked the committee to consider recommending that the label warning be removed. The contraindication poses a medical dilemma for physicians, Pierson pointed out. "I think that upper respiratory tract disorders, especially allergic rhinitis, pollinosis, [and] hay fever, are clear indications for the use of antihistamines," he said. "The problem is, especially if you take care of children and adolescents, many of our patients with asthma are also afflicted with these upper airway disorders. So we are on the immediate horns of a dilemma of when there is a noted contraindication or warning about the use of antihistamines in lower respiratory tract diseases, specifically asthma." At a May 15 conference sponsored by "F-D-C Reports," Pierson called the fact that antihistamines are contraindicated for asthmatics "a scientific myth that has astounded us in its survivability with no data." He noted that the contraindication was based on a belief during the early development of antihistamines that they had anticholinergic or atropine-like activity ("The Pink Sheet" May 21, T&G-5). During the panel meeting, Pierson observed that he made a similar presentation on the labeling issue to the committee in 1982. Two years ago, Pierson said, a committee of the American Academy of Allergy and Immunology issued a position statement that said "revised labeling was clearly needed." Pierson referred to a study in which the antihistamine chlorpheniramine was expected to worsen airway function -- when in fact patients' lung function improved. He also noted that the antihistamine terfenadine (Marion Merrell Dow's Seldane) has been shown to block both early- and late-phase asthmatic responses to allergen challenge and block exercise-induced asthma. Labeling for Seldane contains the statement: "Consideration should be given to potential anticholinergic (drying) effects in patients with lower airway disease, including asthma." The labeling for Janssen's Hismanal (astemizole) contains a very similar statement. OTC antihistamines also contain label warnings against taking the products if a person has asthma. For example, labeling for Parke-Davis' OTC antihistamine Benadryl products have the warning: "Do not take this product if you have asthma, glaucoma, emphysema, chronic pulmonary disease...unless directed by a physician."

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth
UsernamePublicRestriction

Register

PS017600

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel